Latest Cultivation News

Ocean Sciences delivered a sharp increase in seaweed revenue during FY2026, but the audited report also records a A$1.612 million continuing-operations loss, A$2.319 million operating cash outflow and material uncertainty over its ability to continue as a going concern. The renamed ASX-listed group is now seeking up to A$3 million while building out its Indonesian platform.

Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.

Hydrix is ramping up its defence technology efforts, focusing on sensing and autonomous systems aligned with Australia’s $425 billion 2026 National Defence Strategy. The company is developing internal prototypes and forging partnerships to commercialise intellectual property in counter-drone and ISR applications.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Atlas Pearls Ltd (ASX: ATP) faced a tough FY26 with revenue down 42% to $25.8 million and a net loss of $7.9 million, driven by lower pearl quality and softer market conditions. Despite this, the company seeded a record number of oysters and declared a fully franked final dividend of 0.45 cents per share.

Rua Bioscience has gained regulatory approval in New Zealand for five new medicinal cannabis products, setting the stage for domestic sales and advancing its strategy to integrate local cannabis genetics.

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

Rua Bioscience has secured its largest export contract, committing to supply New Zealand-grown medical cannabis flower to a major UK distributor, projecting over NZ$10 million in revenue across two years.

Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.

Germany’s Hesse State Office has issued new GMP guidance that questions the viability of fragmented medicinal cannabis supply chains, reinforcing ECS Botanics’ integrated manufacturing approach and potentially tightening market supply.

Boom Logistics has locked in a five-year extension with BHP at Olympic Dam, underpinning $40 million in annual revenue and reinforcing its long-term partnership strategy.